Moderna turned cutting-edge science into a best-selling product in two years. Robert Cyran explains how its $94 billion valuation is based less on its COVID-19 vaccine than faith that it can do this again repeatedly – and how competition might be a problem
#Moderna #COVID #Vaccines #News #Reuters
Subscribe: http://smarturl.it/reuterssubscribe
Reuters brings you the latest business, finance and breaking news video from around the globe. Our reputation for accuracy and impartiality is unparalleled.
Get the latest news on: http://reuters.com/
Follow Reuters on Facebook: https://www.facebook.com/Reuters
Follow Reuters on Twitter: https://twitter.com/Reuters
Follow Reuters on Instagram: https://www.instagram.com/reuters/?hl=en
#Moderna #COVID #Vaccines #News #Reuters
Subscribe: http://smarturl.it/reuterssubscribe
Reuters brings you the latest business, finance and breaking news video from around the globe. Our reputation for accuracy and impartiality is unparalleled.
Get the latest news on: http://reuters.com/
Follow Reuters on Facebook: https://www.facebook.com/Reuters
Follow Reuters on Twitter: https://twitter.com/Reuters
Follow Reuters on Instagram: https://www.instagram.com/reuters/?hl=en
Sign in or sign up to post comments.
Be the first to comment